Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab plus Steroids for Acute GVHD
NCT00053976Phase 3Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2001
- Primary completion
- Nov 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of daclizumab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Dana-Farber Cancer Institute. Started Jan 2001; status: completed.
02
Drugs
daclizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT00053976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053976.